Antitumor Virotherapy by Attenuated Measles Virus (MV)
AbstractAntitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602.
Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology. 2013; 2(2):587-602.Chicago/Turabian Style
Guillerme, Jean-Baptiste; Gregoire, Marc; Tangy, Frédéric; Fonteneau, Jean-François. 2013. "Antitumor Virotherapy by Attenuated Measles Virus (MV)." Biology 2, no. 2: 587-602.